Unlike PCR, the regions are amplified in E. coli, not in vitro, and thus are subject to review by the E. coli replication machinery. Both of these advances present new options for DNA engineering.

LBP-EC01 is a bacteriophage ‘cocktail’ that has been modified using CRISPR/Cas3 gene-editing to improve its ability to target the E coli genome. Lab studies have demonstrated it is ...

The vaccine, currently in phase 3 trials, targets extraintestinal pathogenic Escherichia coli or ‘ExPEC’, which is estimated to cause around 10 million cases of invasive disease every year and ...